 |
 Video: What is a Stock Split?
|
|
|
| NextCure is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s product candidates include: NC410, which is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR-1) and is designed to block immune suppression mediated by LAIR-1; NC762, which is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, a protein expressed on multiple tumor types; and NC525 (LAIR-1 mAb), which selectively targets Acute Myeloid Leukemia, blast cells and leukemic stem cells. According to our NextCure stock split history records, NextCure has had 0 splits. | |
|
NextCure (NXTC) has 0 splits in our NextCure stock split history database.
Looking at the NextCure stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NextCure shares, starting with a $10,000 purchase of NXTC, presented on a split-history-adjusted basis factoring in the complete NextCure stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/10/2019 |
|
| End date: |
05/06/2024 |
|
| Start price/share: |
$19.50 |
|
| End price/share: |
$1.65 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-91.54% |
|
| Average Annual Total Return: |
-39.01% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$846.19 |
|
| Years: |
4.99 |
|
|
|
|
|
